SCHEMBL731344

SCHEMBL731344

COC(=O)c1cc(OC)c(Br)c(OC)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.53
CA1 P00915 3/20 0.52
CA2 P00918 3/20 0.52
CA12 O43570 2/20 0.52
CA7 P43166 2/20 0.52
CA9 Q16790 2/20 0.52
CA14 Q9ULX7 2/20 0.52
KDM4E B2RXH2 3/20 0.52
ALDH1A1 P00352 2/20 0.52
LMNA P02545 3/20 0.50
POLB P06746 2/20 0.50
GAA P10253 1/20 0.50
NFKB1 P19838 1/20 0.50
XDH P47989 1/20 0.50
GFER P55789 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
FUT7 Q11130 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL731509 0.89 KDM4E (0.58) MAPTCA1CA2CA12CA7
SCHEMBL21821414 0.89 MAPT (0.47) MAPTCA1CA2CA12CA7
SCHEMBL13646593 0.89 CNR2 (0.49) MAPTCA1CA2CA12CA7
SCHEMBL30808280 0.89 MAPT (0.47) MAPTCA1CA2CA12CA7
SCHEMBL732996 0.88 TSHR (0.50) MAPTKDM4ELMNAL3MBTL1CYP3A4
SCHEMBL20763099 0.88 MAPT (0.44) MAPTCA1CA2CA12CA7
SCHEMBL20763421 0.87 KMT2A (0.48) MAPTCA1CA2CA12CA7
SCHEMBL16050010 0.87 MAPT (0.46) MAPTCA1CA2CA12CA7
SCHEMBL28613409 0.86 LCK (0.50) MAPTCA1CA2CA12CA7
SCHEMBL8356857 0.84 MAPT (0.44) MAPTCA1CA2CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112321416-A Method for synthesizing bromocriptine intermediate 4-bromo-3, 5-dimethoxybenzoic acid 李小军 2021-02-05 CN claimed
US-12435066-B2 Substituted tricyclic compounds LUPIN LIMITED (IN) 2025-10-07 US disclosed
WO-2025136811-A1 CHEMICAL COMPOUNDS AND USES THEREOF IDEAYA BIOSCIENCES, INC. (US) 2025-06-26 WO disclosed
US-20250136556-A1 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF ALLIANTHERA BOSTON INC. 2025-05-01 US disclosed
CN-118748992-A Novel modulators of aryl hydrocarbon receptors and methods of use thereof 元启(苏州)生物制药有限公司 2024-10-08 CN disclosed
EP-4430028-A2 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF Allianthera (Suzhou) Biopharmaceutical Co., Ltd. (CN) 2024-09-18 EP disclosed
CN-114957171-B Novel five-membered heterocycle substituted styrene derivative and preparation method and application thereof 广东工业大学 2024-07-30 CN disclosed
CN-114746411-B Substituted tricyclic compounds 印度鲁宾有限公司 2024-06-25 CN disclosed
EP-4065575-B1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LTD (IN) 2024-01-31 EP disclosed
WO-2023086428-A2 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) 2023-05-19 WO disclosed
US-20050059733-A1 Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues WELICHEM BIOTECH, INC. 2005-03-17 US disclosed
EP-1478619-A1 A PROCESS FOR PREPARING A PHENYLALANINE DERIVATIVE AND INTERMEDIATES THEREOF TANABE SEIYAKU CO., LTD. (JP) 2004-11-24 EP disclosed
US-20040224974-A1 7-phenylpyrazolopyridine compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-11-11 US disclosed
WO-2004031117-A1 NOVEL BIOACTIVE DIPHENYL ETHENE COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS WELICHEM BIOTECH INC. (CA) 2004-04-15 WO disclosed
US-20030171429-A1 Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxyltilbenes and novel stilbene derivatives and analogues WELICHEMBIOTECH INC. (CA) 2003-09-11 US disclosed
WO-2003072536-A1 A PROCESS FOR PREPARING A PHENYLALANINE DERIVATIVE AND INTERMEDIATES THEREOF TANABE SEIYAKU CO., LTD. (JP) 2003-09-04 WO disclosed
EP-1248774-A2 POLYHYDROXYSTILBENES AND STILBENE OXIDES AS ANTIPSORIATIC AGENTS AND PROTEIN KINASE INHIBITORS Welichem Biotech Inc. (CA) 2002-10-16 EP disclosed
WO-2001042231-A2 POLYHYDROXYSTILBENES AND STILBENE OXIDES AS ANTISORIATIC AGENTS AND PROTEIN KINASE INHIBITORS WELICHEM BIOTECH INC. (CA) 2001-06-14 WO disclosed
EP-0687249-A1 BALANOIDS ELI LILLY AND COMPANY (US) 1995-12-20 EP disclosed
WO-1994020062-A2 BALANOIDS AS PROTEIN KINASE C INHIBITORS ELI LILLY AND COMPANY (US) 1994-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059733-A1 Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues NFKBIA, IKBKB, IKBKE MAPT 1005/4885CA1 4845/4885CA2 4107/4885
US-20250136556-A1 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF AHR, ARNT, NR1H2 MAPT 4822/4885CA1 4842/4885CA2 4755/4885
US-20040224974-A1 7-phenylpyrazolopyridine compounds CRHR1, MC2R, CRH MAPT 2221/4885CA1 2475/4885CA2 1285/4885
US-20030171429-A1 Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxyltilbenes and novel stilbene derivatives and analogues ROCK1, ROCK2, PTK2 MAPT 2917/4885CA1 4347/4885CA2 4682/4885
US-12435066-B2 Substituted tricyclic compounds SOS1, RSU1, KSR1 MAPT 150/4885CA1 2843/4885CA2 1678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.